Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients from 7 to less than 18 years~* Out patients~* Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria~* Criteria met for ASD on Autism Diagnostic Observation Schedule (ADOS-2) and Autism Diagnosis Interview Revised (ADI-R)~* CGI (Clinical Global Impression) - Severity rating Score ≥ 4~* Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34~* Social responsiveness Scale second edition total score (SRS-2 T-Score) ≥ 66~* Absence of known monogenic syndrome (Fragile X, Rett syndrome ...)~* Absence of any clinically significant abnormality likely to interfere with the conduct of the study according to the judgment of the investigator~Exclusion Criteria:~* Patients not able to follow the study assessments defined by the protocol, with the exception of self-rating questionnaires which will be assessed by parent/legal representative/caregiver for those patients unable to complete them~* Patients having a high suicidal risk according to the investigator judgement~* Chronic renal dysfunction~* Chronic cardiac dysfunction~* Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural therapy~* Severe electrolyte imbalance that is likely to interfere with the study conduct or evaluation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Bumetanide/S95008 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).